Compare Gilead Sciences, Inc. (GILD) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Gilead Sciences, Inc. trades at $133.08 (market cap $163.51B), while Norwegian Cruise Line Holdings Ltd trades at $19.61 (market cap $9.06B). The key difference: Gilead Sciences, Inc. is far larger — about 18× Norwegian Cruise Line Holdings Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| GILD | NCLH | |
|---|---|---|
Market Cap | $163.51B | $9.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $26.94 |
52-Week Low | $108.22 | $14.79 |
Enterprise Value | $178.05B | $24.03B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Norwegian Cruise Line Holdings (NCLH) trades at $19.46, down 0.87% on the day, with technical indicators showing a neutral to bearish short-term bias. The company has demonstrated consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations of $0.15. Revenue growth has been steady, reaching $9.83 billion in 2025, while profitability metrics show a net income margin of 5.66% and strong ROE of 29.53%. Recent news highlights include positive coverage of Caribbean sailings and a new chief marketing officer appointment.
NCLH presents a mixed investment case with analyst consensus leaning bullish (55.55% buy ratings) and a $21.71 price target offering 11.6% upside. However, elevated debt levels ($11.78 billion long-term debt) and macroeconomic sensitivity pose significant risks. The stock's current valuation at 15.91x P/E appears reasonable relative to historical levels, but investors should weigh the company's operational recovery against ongoing balance sheet concerns and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
